- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07784478
Effect of Oxytocin Bolus Versus Slow Infusion on Haemodynamic Stability During Caesarean Section Under Spinal Anaesthesia
Effect of Oxytocin Administration Technique on Haemodynamic Stability During Caesarean Section Under Spinal Anaesthesia: A Randomised Controlled Trial
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Postpartum haemorrhage remains a leading cause of maternal mortality worldwide. Oxytocin is the first-line uterotonic agent used after delivery of the baby during caesarean section. When given as a rapid intravenous bolus, oxytocin can cause significant hypotension, tachycardia and other haemodynamic changes, especially in women under spinal anaesthesia.
This prospective, randomised, controlled trial will compare the haemodynamic effects of oxytocin 5 IU administered as a rapid intravenous bolus versus the same dose given as a slow intravenous infusion over 15 minutes in women undergoing elective caesarean section under spinal anaesthesia.
Sixty women aged 18-40 years with singleton pregnancy at 37-42 weeks, ASA physical status I or II, will be randomly allocated to one of two groups:
Group A (Bolus): Oxytocin 5 IU given as an intravenous bolus over 15 seconds immediately after umbilical cord clamping.
Group B (Infusion): Oxytocin 5 IU diluted and infused over 15 minutes via syringe pump immediately after umbilical cord clamping.
The primary outcome is the change in systolic blood pressure from baseline at 2, 5 and 10 minutes after oxytocin administration. Secondary outcomes include changes in diastolic blood pressure and heart rate, incidence of hypotension and tachycardia, vasopressor requirements, uterine tone assessed by a 5-point scale, estimated blood loss, and side effects such as nausea, vomiting, flushing and chest discomfort.
The study will be conducted at Hayatabad Medical Complex, Peshawar. All participants will receive standard spinal anaesthesia and routine care. The results are expected to provide local evidence to support safer oxytocin administration practices during caesarean section under spinal anaesthesia.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Fareeha Zahir, MBBS / FCPS-II Trainee
- Número de teléfono: +923319932275
- Correo electrónico: fareehak933@gmail.com
Ubicaciones de estudio
-
-
Khyber Pakhtunkhwa
-
Peshawar, Khyber Pakhtunkhwa, Pakistán, 25000
- Hayatabad Medical Complex / Khyber Girls Medical College
-
Contacto:
- Fareeha Zahir, MBBS / FCPS-II Trainee
- Número de teléfono: +923319932275
- Correo electrónico: fareehak933@gmail.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Adult female patients aged 18 to 40 years
- American Society of Anesthesiologists (ASA) physical status class I or II
- Singleton pregnancy at 37 to 42 weeks gestational age
- Scheduled for elective caesarean section under spinal anaesthesia
- Written informed consent obtained
Exclusion Criteria:
- Patients with anticipated hemodynamic instability including severe preeclampsia/eclampsia, placenta previa with active bleeding, placental abruption, or hemorrhagic shock
- Pre-existing cardiovascular disease including ischemic heart disease, valvular heart disease, cardiomyopathy, or arrhythmias
- Baseline systolic blood pressure < 100 mmHg or heart rate > 100 bpm before spinal block
- Known hypersensitivity to oxytocin
- Failed spinal anaesthesia requiring conversion to general anaesthesia
- Patients receiving medications that may alter the hemodynamic response to oxytocin (beta-blockers, calcium channel blockers, ACE inhibitors, or angiotensin receptor blockers)
- Pre-existing anaemia (Hb < 8 g/dL)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: Bolus Group
Participants will receive oxytocin 5 IU in 1 mL normal saline as an intravenous bolus over 15 seconds immediately after umbilical cord clamping, followed by 9 mL normal saline infusion over 15 minutes (to maintain blinding).
|
Oxytocin 5 IU administered either as a rapid intravenous bolus over 15 seconds or as a slow intravenous infusion over 15 minutes immediately after umbilical cord clamping during elective caesarean section under spinal anaesthesia.
Otros nombres:
|
|
Experimental: Infusion Group
Participants will receive oxytocin 5 IU diluted in 50 mL normal saline administered via syringe pump over 15 minutes immediately after umbilical cord clamping.
A simultaneous 1 mL normal saline bolus will be given over 15 seconds to maintain blinding of the initial injection.
|
Oxytocin 5 IU administered either as a rapid intravenous bolus over 15 seconds or as a slow intravenous infusion over 15 minutes immediately after umbilical cord clamping during elective caesarean section under spinal anaesthesia.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Systolic Blood Pressure (SBP) from Baseline
Periodo de tiempo: Baseline; 2 minutes, 5 minutes, and 10 minutes after oxytocin administration
|
Change in systolic blood pressure from baseline (mean of three pre-anaesthesia readings) measured at 2, 5, and 10 minutes after oxytocin administration.
|
Baseline; 2 minutes, 5 minutes, and 10 minutes after oxytocin administration
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Diastolic Blood Pressure and Heart Rate from Baseline
Periodo de tiempo: 1, 2, 3, 5, 10, 15, and 20 minutes after oxytocin administration
|
Change in diastolic blood pressure and heart rate from baseline at defined time points after oxytocin administration.
|
1, 2, 3, 5, 10, 15, and 20 minutes after oxytocin administration
|
|
Incidence of Clinically Significant Hypotension
Periodo de tiempo: Within 20 minutes after oxytocin administration
|
Proportion of participants who develop systolic blood pressure < 90 mmHg or a fall of > 20% from baseline after oxytocin administration.
|
Within 20 minutes after oxytocin administration
|
|
Uterine Contraction Scale Score
Periodo de tiempo: 5 minutes after placental delivery
|
Uterine tone assessed by the operating obstetrician using a 5-point scale (Grade 1 = atonic to Grade 5 = very well contracted) at 5 minutes after placental delivery.
Grade 1 or 2 is classified as uterine atony.
|
5 minutes after placental delivery
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Enfermedades Vasculares
- Enfermedades cardiovasculares
- Procesos Patológicos
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Complicaciones obstétricas del parto
- Complicaciones del embarazo
- Hemorragia
- Trastornos Puerperales
- Hemorragia uterina
- Condiciones Patológicas, Signos y Síntomas
- Hipotensión
- Hemorragia post parto
- Hormonas
- Hormonas, sustitutos hormonales y antagonistas hormonales
- Hormonas peptídicas
- Péptidos
- Aminoácidos, péptidos y proteínas
- Hormonas pituitarias, posterior
- Hormonas pituitarias
- Oxitocina
Otros números de identificación del estudio
- CHR-IREB-2026-0050
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .